Diagnosis & Disease Information

pulmonary fibrosis

New Data Support the Efficacy of TXR-1002 for IPF Treatment

Aria Pharmaceuticals revealed promising results from the third preclinical study of TRX-1002, an idiopathic pulmonary fibrosis (IPF) treatment candidate, that showed a significant decrease in absolute lung weight, fibrosis score, and collagen and hydroxyproline levels.   The findings, revealed in a press release, were presented at the 6th Annual Antifibrotic Drug Development Summit in Boston, Massachusetts. “People suffering from…

Next post in IPF News Briefs